A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.

Although four randomized phase III trials that evaluated the efficacy of concurrent erlotinib or gefitinib administration with standard platinum-doublet chemotherapy failed to show evidence of improved survival [ 11 - 14 ], the phase II First-Line Asian Sequential Tarceva and Chemotherapy Trial (FAST-ACT) proved that the sequential administration of TKI following chemotherapy led to a significant improvement in progression-free survival (PFS; P = 0.0002) and patients showed a trend toward a better tumor response rate (35.5% versus 24.4%; P = 0.12) [ 15 ].

also in 53,322 other papers